Insights / Resource Center
Primrose Bio's Resource Center
Events
Primrose Bio at BIO International Convention 2025
Primrose Bio joined BIO 2025 in Boston to showcase innovations in RNA polymerase, protein expression, and CRM197 carrier protein for next-gen therapeutics.
Primrose Bio Presents at Oxford Nanopore Biopharma Day
On June 12, 2025, Tyler Dang, PhD represented Primrose Bio at Oxford Nanopore Technologies’ inaugural Biopharma Day in San Diego. This regional event brought together...
Primrose Bio Highlights High-Throughput Enzyme Screening at Cytiva’s Process Development Virtual Summit
At Cytiva’s Process Development Summit, Primrose Bio showcased a high-throughput enzyme screening method using Protein Select™ and Pfenex Expression Technology®.
Webinars
Pfast™ Protein Expression
Achieving High Quality Efficient mRNA Synthesis
Scientific Posters
Presented at TIDES USA 2025: Prima RNApols™ ExTend: rewriting the rules of long mRNA manufacturing
ABSTRACT: The success of mRNA COVID-19 vaccines has transformed the therapeutic landscape, accelerating the development of mRNA-based treatments across diverse applications. While in vitro...
Presented at TIDES USA 2025: Advancing mRNA therapeutics with high performance RNA polymerases
ABSTRACT: RNA has emerged as a critical tool in modern biotechnology and therapeutics, with applications ranging from vaccine development to gene therapy. mRNA is synthesized by in vitro...
Presented at PEGS US 2025: High-Throughput Expression and Purification of Untagged RNA Polymerase Variants: Advancements in the Pfenex Expression Technology® Platform
ABSTRACT: Primrose Bio's Pfenex Expression Technology® (Pfenex) platform has established itself as a robust, scalable solution for recombinant protein production, as evidenced by its role in six...
Case Studies
Pfenex
Recombinant Erwinia Asparaginase Production
Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children. Lymphoblastic lymphoma (LBL) is a rare, fast-growing, aggressive subtype of non-Hodgkin’s lymphoma most often seen in teenagers and young adults.
Pfenex
Production of disulfide-rich cow knob domain antibodies: picobodies™
About 10% of cow antibodies have exceptionally long heavy chain CDR3 regions, including a stalk and knob region.
Pfenex
Multimeric vhh nanobody expression
Pfenex
Fab antibody fragment titer improvement
Anti-IL-4 Conjugate Vaccine Prepared with Pfenex CRM197 is More Immunogenic than KLH Analog
